The diffusing capacity of the lung for carbon monoxide (DLCO) is indicative of the alveolar-capillary membrane function. A reduced DLCO is associated with poor prognosis in chronic heart failure (HF). However, the significance of DLCO as an independent prognostic predictor has not been established. Here, we aimed to determine the prognostic value of DLCO in patients with chronic HF.
H eart failure (HF) currently affects more than 23 million people worldwide. The exacerbation of this disease increases the risk of severe morbidity and mortality, with structural and functional effects on multiple organs, as indicated by associated conditions such as metabolic disorders, liver and renal insufficiency, and pulmonary function disorders. Many reports have suggested that age, body mass index, blood pressure, anemia, liver damage, renal function, and pulmonary function are prognostic factors of HF as well as cardiac function. [1] [2] [3] Regarding the latter factors, various tests have been devised to measure the pulmonary function, including vital capacity (VC), forced expiratory volume in one second (FEV1.0), and diffusing capacity of the lung for carbon monoxide (DLCO). VC is the volume of air exhaled after the deepest inhalation, and FEV1.0 is the volume exhaled at the end of the first second of forced expiration. In patients with HF, both VC and FEV1.0 are reduced [4] [5] [6] because of the attenuation of the respiratory muscles 7) and reduced lung volume due to cardiomegaly. 8) DLCO measures the transfer of gases from air in the lungs to the red blood cells in pulmonary blood vessels and can therefore determine the ability of the lungs to transport gas into and out of the blood. DLCO is determined on the basis of the alveolar-capillary membrane diffusing capacity and capillary blood volume. The former is known to decrease under conditions that affect the effective alveolar surface area (e.g., chronic obstructive pulmonary disease), 9) or pulmonary vasculature (e.g., pulmonary embolism), 10) or impairment of membrane permeability (e.g., smoking and interstitial pneumonia). 11, 12) Notably, reduced DLCO has been reported in patients with HF, suggesting the occurrence of pulmonary endorgan damage. [4] [5] [6] 13, 14) However, the significance of DLCO as an independent predictor of prognosis has not been established in the context of HF treatment. Accordingly, we aimed to address the prognostic value of DLCO relative to other known predictors in patients with stable chronic HF.
Methods
Study population: This study was designed as a retrospective analysis of data from 1,879 patients with heart disease admitted to the Heart Failure Division at the De-DLCO IN CHRONIC HF 
stable HF for more than three months, and (4) a follow-up period of more than one year after pulmonary function testing. "Stable" was defined as no change in New York Heart Association (NYHA) functional class and absence of cardiac decompensation. Previous and current smokers, patients who had received amiodarone therapy for more than one month, and those with congenital heart diseases or pulmonary artery diseases were excluded. Diagnoses of hypertension were established on the basis of the patients' medical records. Demographic and clinical data, including age, sex, NYHA functional class, medication, and prior decompensated HF admission, were collected from the hospital's medical records. The institutional review board approved this study and waived informed consent (M26-143-2). Pulmonary function tests: Patients underwent spirometry with stable conditions performed by experienced technologists using a FUDAK-77 (Fukuda Electronic Inc., Tokyo, Japan) in conformity with the American Thoracic Society/ European Respiratory Society (ATS/ERS) standard. 15) DLCO was determined using the single-breath method, as recommended by the ATS/ERS. Pulmonary function tests also included measurements of VC and FEV1.0. VC, FEV 1.0, and DLCO were expressed as percentages of the predicted values (%VC, %FEV1.0, and %DLCO, respectively). The predicted values of VC, FEV1.0, and DLCO were calculated using the equations devised by Baldwin, Berglund, and Burrows, respectively. [16] [17] [18] Echocardiography: All patients underwent comprehensive transthoracic echocardiographic studies, including Mmode, two-dimensional echocardiography, continuous and pulsed wave Doppler, and color Doppler, according to the guidelines for the clinical application of echocardiography. 19) Data concerning the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction (LVEF), and left atrial volume indexed to body surface area (LAVi) were extracted. Blood evaluation: All patients underwent blood evaluation while in a stable condition. The estimated glomerular filtration rate (eGFR), a measure of renal function, was calculated using an abbreviated Modification of Diet in Renal Disease (MDRD) equation, modified using a Japanese coefficient. 20) Anemia was defined according to the World Health Organization (WHO) criteria (hemoglobin: < 13.0 g/dL in men and < 12.0 g/dL in women). The concentration of plasma brain natriuretic peptide (BNP) was measured using an immunoradiometric assay (ShionoRIA BNP; Shionogi & Co., Osaka, Japan). Cardiac catheterization: Pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP), and right atrial pressure (RAP) were measured with a balloontipped pulmonary artery catheter. Cardiac output was determined using the Fick method and indexed to the body surface area (cardiac index). Aortic pressure (AoP) was measured with a 5 Fr pigtail catheter. Outcome measures: The primary endpoint was defined as the occurrence of adverse cardiac events, including death from any cause, cardiopulmonary arrest (CPA), left ventricular assist device (LVAD) implantation, or unplanned admission for acute decompensated HF. Statistical analysis: Continuous variables are expressed as mean ± standard deviation (SD) or median (interquartile range, IQR). Categorical data are expressed as count and percentage. Continuous variables were compared using one-way analysis of variance. Categorical variables were analyzed using the chi-squared test. Linear correlations were assessed using Pearson's correlation coefficient. Cardiac adverse-event-free curves were constructed using the Kaplan-Meier method, and differences were compared using the log-rank test. For this analysis, patients were stratified according to the median %DLCO value (< 87.3% or "87.3%). Based on previous reports regarding long-term prognosis, 2, [21] [22] [23] [24] [25] [26] the following potential confounders were considered in the Cox proportional hazard analysis: age (< 75 or "75 years), sex, systolic blood pressure (SBP) (WHO criteria: !90, 91-140, or > 140 mmHg), LVEF (< 45% or "45%), anemia (WHO criteria), BNP (< 100 or "100 pg/mL), eGFR (< 60 or "60 mL/minute/1.73 m 2 ), and prior decompensated HF admission. A P-value of < 0.05 was considered statistically significant. Statistical analyses were performed using JMP 11 (SAS Institute Inc., Cary, NC, USA).
Results

Patient population:
The characteristics of the 214 consecutive inpatients enrolled in this study are summarized in Tables I and II . Pulmonary function tests and all other examinations were performed almost within a week. There were no patients receiving anti-pulmonary-hypertension medications. As shown in Table I , pulmonary function test data yielded the median of DLCO and %DLCO predicted values of 14.5 mL/minute/mmHg (IQR: 11.7-18.0) and 87.3% (IQR: 75.7-102.4), respectively. Table II presents the characteristics of patients divided into two groups according to the median %DLCO value of 87.3%. The mean patient age was 63 ± 16 years, and 75 (35%) patients were males. Regarding NYHA functional class, 47 (22%), 147 (69%), and 20 (9%) patients had class I, class II, and class III or IV HF, respectively. Half of the study patients had a history of hospitalization for acute decompensated HF. The HF etiology NAKAMURA, ET AL 
Data are expressed as mean ± SD. NYHA indicates New York Heart Association; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LAVi, left atrial volume indexed to body surface area; T-bil, total bilirubin; ALT, alanine aminotransferase; Na, serum sodium; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; Hb, hemoglobin; BNP, brain natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ADHF, acute decompensated heart failure; LVAD, left ventricular assist device; CPA, cardiopulmonary arrest; and HF, heart failure.
was idiopathic dilated cardiomyopathy in 66 (31%) patients, hypertrophic cardiomyopathy in 28 (13%) patients, and ischemic cardiomyopathy in 24 (11%) patients. The mean LVEF was 43 ± 19%, with a mean BNP level of 233 ± 301 pg/mL. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers were prescribed to 129 (60%) patients, beta-blockers were prescribed to 145 (68%) patients, and diuretics were prescribed to 115 (54%) patients. Patients with a %DLCO of < 87.3% differed significantly from those with a %DLCO of !87.3% in the following ways: (1) higher prevalence of NYHA class II or III, anemia, and prior decompensated HF admission; (2) lower LVEF and larger left atrium; (3) higher blood urea nitrogen, creatinine, and C-reactive protein levels and lower hemoglobin, eGFR, and serum sodium levels; and (4) higher rate of prescriptions for aldosterone blockers and loop diuretics. %DLCO in chronic HF: As shown in Figure 1 , the % DLCO tended to decrease along with the deterioration of the NYHA functional class; in other words, %DLCO was significantly lower in patients with NYHA III-IV disease than in those with NYHA II disease (P < 0.001).
Pulmonary function and hemodynamics:
Cardiac catheterization data were available for 87 out of 214 (41%) patients. Figure 2 presents Kaplan-Meier survival curves of patients divided according to the median %DLCO value. Notably, the event-free survival rate was significantly lower in the lower %DLCO group (P = 0.001). Table IV presents the results of a Cox proportional hazard analysis to estimate the hazard ratios (HRs) of composite adverse events in the two groups of patients divided by %DLCO. The unadjusted HR of these events was 2.51 times higher in patients with a %DLCO of < 87.3% than in those with a %DLCO of !87.3% (P = 0.001). Even after adjusting for age, sex, SBP, LVEF, anemia, BNP, eGFR, and prior HF admission, %DLCO < 87.3% remained an independent predictor of cardiac adverse events (HR: 1.87, P = 0.030).
Discussion
In the present study, we demonstrated an independent NAKAMURA, ET AL Figure 2 . Kaplan-Meier estimations of cardiac events according to %DLCO. The cardiac adverse-event-free rate was significantly lower in the lower %DLCO group. HR indicates hazard ratio; and %DLCO, percent predicted diffusing capacity of the lung for carbon monoxide. HR indicates hazard ratio; CI, confidence interval; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; %DLCO, percent predicted diffusing capacity of the lung for carbon monoxide; and HF, heart failure.
association between reduced %DLCO and an increased incidence of adverse cardiac events, including death, CPAs, LVAD implantations, and acute decompensated HF, in 214 patients with stable chronic HF who lacked a history of smoking and amiodarone use. Although the pulmonary function has been previously associated with the prognosis of patients with HF, to the best of our knowledge, this is the first study identifying reduced %DLCO as an independent predictor even after adjusting for known prognostic variables. Deterioration of DLCO in patients with stable chronic HF-Alveolus-capillary remodeling: As shown in Table  III , our results are consistent with those of previous studies in which %VC, but not DLCO, was found to be associated with PAP and PCWP. 5) Furthermore, earlier research failed to demonstrate improvements in DLCO following heart transplantation, despite the improved hemodynamics. 27) These results suggest that impaired DLCO might represent persistent alveolus-capillary damage, rather than the pulmonary fluid status. In patients with severe HF, inflammation is known to coexist with pulmonary congestion after overexercizing or temporary body fluid gain without admission for acute HF. 28, 29) Pathological inflammation can induce the permeation of proteins and cytokines into the pulmonary stroma, which may cause alveolus and capillary wall thickening as a result of collagen hyperplasia and structural changes in the pulmonary stroma. [30] [31] [32] [33] [34] In addition, ACEIs and sildenafil reportedly improve DLCO, supporting the concept that neurohormonal activation in the context of HF can induce an alveolar-capillary thickening process. 35, 36) This mechanism might have a stronger influence on alveolus-capillary damage, leading to pulmonary congestion, than on the current hemodynamics. As shown in Table V was significantly correlated with TPG. This finding implies that DLCO reflects the pulmonary structure remodeling.
37)
Relation to HF severity and prognostic value of DLCO: Puri, et al. 4) reported significant reductions in DLCO in patients with congestive HF relative to normal subjects (72 ± 15%, 80 ± 25%, and 105 ± 11% in NYHA functional class III, NYHA functional class II, and normal subjects, respectively). Agostoni, et al. 6) demonstrated the lowest DLCO values in patients with severe HF, as well as a linear correlation with peak VO2. Similarly, in our study, we also found that %DLCO was reduced along with decreasing NYHA functional class, confirming that DLCO reflects the severity of congestive HF.
Furthermore, Olson, et al. 38) described significant differences in the rates of death and heart transplantation between HF patients with a %DLCO of < 75% and those with a %DLCO of > 96%. Guazzi, et al. 13 ) measured DLCO along with its subcomponent alveolar-capillary membrane conductance and reported a higher rate of death among HF patients with a lower membrane conductance. Our study contributed to the novel finding that even a small decrease in %DLCO contributes to the long-term prognosis of patients with HF.
Compared with previous studies, the present study is characterized by the exclusion of smokers and patients who received amiodarone therapy. Although some previous studies included ex-smokers, this population is reported to have a decreased DLCO. 39 ) Therefore, we strictly excluded patients with a smoking history as well. In addition, amiodarone therapy for more than one month can cause amiodarone-induced pulmonary toxicity. 40) The exclusion of these patients may help clarify the results of the present study, although the meaning of the results should be interpreted carefully. Clinical implication: In this study, we identified impaired DLCO as an independent prognostic predictor in patients with stable chronic HF. We implicated that DLCO reflects alveolus-capillary structure remodeling via interstitial inflammation caused by subclinical temporal exertional pulmonary congestion or volume overload, which would not be recognized by clinical testing performed in a resting state. The measurement of %DLCO may allow noninvasive and easily repeatable assessments of the alveolar remodeling associated with congestive HF. Therefore, an impaired DLCO may indicate the need for more cautious treatment, because the impairment of DLCO may lower the threshold of development of HF symptoms. However, whether impaired DLCO can cause the progression of HF and whether DLCO can be a therapeutic target for HF are unclear, which we would like to investigate in the following study. Study limitations: This study had some limitations. First, the number of subjects was small, it was a single-center study, and its design was retrospective in nature. In this study period, there were no definite criteria for performing pulmonary function tests in hospitalized patients with chronic HF. Therefore, our results need be confirmed in a larger population comprising more severe cases, as well as a randomized prospective study to avoid the selection bias and to determine the true %DLCO cut-off value for predicting cardiac events. Second, DLCO represents not only the alveolar-capillary membrane function, but also the capillary blood volume, and reductions in %DLCO are partially emphasized by pulmonary congestion, particularly in severe HF. Accordingly, it might be difficult to completely determine whether impaired DLCO is attributable to fluid accumulation or structural remodeling in the lung, despite performing pulmonary function tests in a stable chronic state. Third, because our parameters were selected to investigate the clinical significance of DLCO according to the past reports, multicollinearity may affect the results in the present study. Besides the conventional parameters that we selected in this study, various prognostic factors have been reported. [41] [42] [43] In the next study, we will reselect parameters for the analysis, considering also the multicollinearity.
